福安藥業(300194.SZ):2019年度扭虧為盈 預盈2.9億元-2.95億元
格隆匯1月20日丨福安藥業(300194.SZ)披露2019年度業績預告,公司預計2019年1-12月歸屬於上市公司股東的淨利潤為2.9億元-2.95億元,上年同期虧損約3.6億元。業績變動原因如下:
(一)業績變動情況
本報告期,公司歸屬於上市公司股東的淨利潤與去年同期比較實現扭虧為盈,扣除上年同期計提商譽減值影響後,本期歸屬於上市公司股東的淨利潤同比增長17.52%-19.54%,業績變動主要原因為:
(1)上年公司全資子公司福安藥業集團只楚藥業有限公司商譽減值計提減值準備6.07億元,造成上年淨利潤虧損。
(2)本期公司製劑產品營業收入和銷售毛利穩步增長。
(3)本期公司參股的聯營企業重慶富民銀行股份有限公司經營業績增長,公司確認投資收益同比增加。
(二)、非經常性損益的影響
本報告期,公司非經常性損益對淨利潤的影響額為3200萬元左右,主要為公司取得的政府補助收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.